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Abstract: The number of dementia patients has been growing in recent years and dementia represents a significant threat 
to aging people all over the world. Recent research has shown that the number of people affected by Alzheimer’s disease 
(AD) and dementia is growing at an epidemic pace. The rapidly increasing financial and personal costs will affect the 
world's economies, health care systems, and many families. Researchers are now exploring a possible connection among 
AD, vascular dementia (VD), diabetes mellitus (type 2, T2DM) and cardiovascular diseases (CD). This correlation may be 
due to a strong association of cardiovascular risk factors with AD and VD, suggesting that these diseases share some 
biologic pathways. Since heart failure is associated with an increased risk of AD and VD, keeping the heart healthy may 
prove to keep the brain healthy as well. The risk for dementia is especially high when diabetes mellitus is comorbid with 
severe systolic hypertension or heart disease. In addition, the degree of coronary artery disease (CAD) is independently 
associated with cardinal neuropathological lesions of AD. Thus, the contribution of T2DM and CD to AD and VD implies 
that cardiovascular therapies may prove useful in preventing AD and dementia.  
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INTRODUCTION 
  Recent epidemiologic and clinico-pathologic data suggest 
overlaps between AD and cerebrovascular lesions that may 
magnify the effect of mild AD pathology. This interaction 
may promote the progression of cognitive decline or even 
precede neuronal damage and dementia. Vascular pathology 
in the aging brain and in AD includes cerebral amyloid 
angiopathy (CAA), multiple or recurrent micro-
haemorrhages and ischaemic infarcts. AD cases with 
additional minor cerebrovascular lesions are much more 
likely to have a history of hypertension or infarcts than 
"pure" AD patients. There is a documented association of 
low plasma amyloid-beta peptide ratios (A42/A40) with 
increased imminent risk for mild cognitive impairment and 
AD [1]. The observation that the nerve growth factor 
receptor (NGFR, also known as neurotrophic tyrosine kinase 
receptor 1 (NTRK1) or TRKA) is down-regulated in AD 
brains led to the suggestion that an imbalance in 
NGF/NTRK1 signalling might be involved in AD [2-4]. 
Heart-derived NGF also regulates the survival and 
maintenance of sympathetic neurons that innervate the heart 
and is a crucial factor in myocardial ischaemia, a main cause 
of sudden death in diabetes mellitus [5]. Thus, researchers 
are currently exploring the possibility of a connection among 
AD, VD, T2DM and CD [6, 7]. The risk for dementia is 
especially high when T2DM occurs together with severe 
systolic hypertension or heart disease. In addition, the degree 
of CAD is independently associated with the cardinal 
neuropathological lesions of AD [8]. Consequently, the 
association of heart failure with an increased risk of AD and  
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VD suggests that the general advice to keep the heart healthy 
may prove to keep the brain healthy as well [9]. The strong 
association of cardiovascular risk factors with AD and VD 
suggests that these diseases share some biologic pathways. 
The contribution of cardiovascular disease to AD and VD 
implies that cardiovascular therapies may prove useful for 
the treatment or prevention of AD and dementia [10-13]. 
Since NGF has also been discussed as a crucial molecule in 
diabetic nephropathy [14], it is considered a potential 
biomarker for AD and neuro-immune diseases [15-17]. This 
review intends to unravel some potential links among 
various diseases including AD, VD, T2DM and CD. 
ALZHEIMER’S DISEASE 
  AD is a progressive neurodegenerative disorder that is 
characterised by two types of proteinaceous deposits in the 
brain: extracellular amyloid plaques and intracellular 
neurofibrillary tangles (NFTs). The term “Alzheimer’s 
disease” was coined after the name of its discoverer, Alois 
Alzheimer, a German neuropathologist who first described 
the symptoms of this disease in a 51-year-old patient named 
“Auguste”. AD is a specific neurodegenerative disease and 
remains the most common cause of dementia among the 
elderly. Today, approximately 37 million people worldwide 
suffer from diverse forms of dementia, and about 18 million 
of them have AD [18]. The number of patients afflicted with 
AD is expected to rise and double by the year 2025. AD 
disrupts communication between brain regions by causing 
neurons to lose functionality and die [19]. Common 
symptoms of AD include progressive loss of memory and 
cognitive dysfunctions such as language deterioration, 
impaired visuospatial skills, poor judgement, inability to 
learn new things, indifference, depression, delusions and 
other manifestations [20]. AD primarily affects the cerebral 
cortex (grey matter) of the temporal lobe (involved in 
memory, auditory stimuli and speech), the parietal lobe 30    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
(involved in orientation, recognition and perception of 
stimuli) and the frontal lobe (used for reasoning judgment, 
emotions, movement and speech) of the brain. Deeper 
structures of the brain, such as the hippocampus (involved in 
memory and learning processes), and the amygdala 
(involved in emotional drives), are also affected in AD [21]. 
  AD is classified into two subsets: early onset familial AD 
(FAD) and late onset sporadic AD (SAD). FAD is very rare 
and has been found in relatively small numbers of families 
[22]. Three genes account for the less prevalent FAD: 
presenilin1 (PS1), PS2 and the amyloid precursor protein 
(APP) [23]. Mutations in the APP gene, which is located on 
chromosome 21, have been postulated to play a major role in 
the aggregation of a clumped sticky protein fragment known 
as A [24]. The PS1 and PS2 genes are located on 
chromosomes 14 and 1, respectively. Mutations in the PS1 
gene causes enhanced proteolytic processing of APP and 
lead to the most aggressive form of FAD. Evidence from 
rodent studies suggests that PS1 mutation results in impaired 
hippocampus-dependent learning, which also correlates with 
reduced adult neurogenesis in the dentate gyrus [25]. 
  SAD is the most prevalent form of the disease, affecting 
about 90% of AD patients. It affects people over the age of 
65, including around 50% of all people over the age of 85. 
SAD is not caused by a specific gene mutation. The most 
studied gene in SAD is ApoE (polymorphic protein), which 
is responsible for the production of a protein involved in 
cholesterol and lipid transport. It exists in three forms, or 
alleles, named ApoE2,
  ApoE3, and ApoE4. The ApoE4 
allele is a well-established
 risk factor for SAD [26]. 
  Based on AD research over the past 50 years, three main 
hypotheses have been discussed. The oldest hypothesis is the 
“cholinergic hypothesis”, which states that AD begins as a 
deficiency in the production of acetylcholine (ACh), a vital 
neurotransmitter [27]. Loss of cholinergic neurons is coupled 
specifically with typical clinical symptoms such as memory 
deficits, impaired attention, cognitive decline and reduced 
learning abilities. The other two hypotheses are called the 
“Tau-ist” hypothesis and the “ba-ptist” hypothesis. Due to 
the accumulation of abnormally folded A and Tau proteins 
in the brains of AD patients, AD has also been called a 
protein misfolding disease (proteopathy) [28]. 
  Glucose is transported across the blood brain barrier 
(BBB) into the extracellular space through specific glucose 
transporters such as GLUT1. Glucose that enters the 
glycolytic pathway forms Acetyl-CoA. The memory 
enhancing and memory stabilising neurotransmitter ACh is 
produced from Acetyl-CoA and choline under the control of 
insulin. ACh can then bind to nicotinic and muscarinergic 
ACh receptors that are thus also targets for the treatment of 
AD [29-31]. In addition, the binding of ACh to its 
muscarinergic m1 and m3 receptors can then stimulate the 
formation of soluble APP (sAPP). sAPP in turn can then 
modulate synaptic plasticity in the hippocampus and 
promotes dendritic outgrowth [32]. 
 The “Tau-ist” hypothesis revolves around the 
microtubule-associated protein Tau (MAPT) [33]. Healthy 
neurons have an internal cytoskeleton, partly made up of 
structures called microtubules. Microtubules play an 
important role in nutrient and neurotransmitter transport, 
structural integrity and cell regulation within neurons. They 
are mainly present in neuronal axons. The Tau protein helps 
to stabilise the microtubules through phosphorylation [34, 
35]. However, in AD the Tau proteins become 
hyperphosphorylated and lose the ability to bind to 
microtubules. Instead, the hyperphosphorylated Tau proteins 
bind to each other and tie themselves into “knots” known as 
NFTs [36]. These NFTs destabilise microtubules and 
collapse the neuronal transport system. Hence, NFT 
formation results in malfunctions of the microtubule-
mediated transport system as well as in communication 
among neurons, eventually leading to apoptosis [37].  
  According to the “Ba-ptist” hypothesis, A deposits are 
the causal factor for the disease. This theory is gaining 
popularity among scientists because of the recently 
discovered impaired vascular and cerebrospinal fluid (CSF) 
transport of A peptides out of the brain and the resulting 
increase in risk for senile plaque (SP) formation [38, 39]. 
SPs and NFTs are associated with a loss of neurons and 
synapses, brain atrophy and dilatation of the lateral 
ventricles (due to a loss of brain tissue) [40, 41].  
  APP is a type-I transmembrane protein that has an 
extracellular N-terminal domain and a short intracellular C-
terminal domain. This protein is expressed in many cell 
types that include neurons in the central nervous system 
(CNS). APP undergoes non-amyloidogenic cleavage by the 
–secretase, releasing soluble sAPP (Fig. 1) [42]. The 
release of sAPP from neurons has been implicated in neurite 
outgrowth and serine protease inhibitor function [43]. A 
second cleavage by –secretase results in the extracellular 
secretion of small p3 peptides and the intracellular release of 
the cytoplasmic tail AICD (APP intracellular domain). Once 
released, AICD is thought to act as a transcriptional activator 
and to perform other signalling roles. In contrast, the 
amyloidogenic cleavage of APP is initiated by -secretase 
cleavage, a -site APP-cleaving enzyme (BACE) that 
releases soluble sAPP [44]. The second part of this 
pathogenic cleavage is mediated by the -secretase, 
generating a 40 amino acid amyloid peptide (A40) that is 
soluble and innocuous or a 42 amino acid peptide (A42) 
that clumps to form insoluble amyloid plaques. The non-
amyloidogenic pathway probably occurs in the Golgi 
network and at the cell surface, whereas the amyloidogenic 
-secretase pathway is initiated at the endoplasmic reticulum 
(ER) [45].  
DIABETES 
  All living organisms need energy to function, and 
glucose is a potential energy source. The amount of glucose 
in the bloodstream is regulated by various hormones, the 
most important of which is insulin. Blood glucose levels are 
not constant; the level fluctuates depending on the body’s 
daily needs and hormonal regulations. Under normal 
conditions, the glucose levels range between 70 and 110 
mg/dl. The blood glucose level may rise for three reasons: 
diet, breakdown of glycogen or hepatic synthesis of glucose. 
For the human body to function properly, an optimum level 
of glucose must be maintained in the blood. Extreme 
fluctuation of the level of glucose in the blood leads to 
various consequential phenotypes. For instance, diabetes is a 
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subgroups: type-1 diabetes mellitus (T1DM) and type-2 
diabetes mellitus (T2DM). This classification is based on 
whether the elevation of blood glucose level is the result of 
insulin deficiency (T1DM) or insulin resistance (T2DM) 
[46]. T1DM is an autoimmune disease that occurs when low 
levels of insulin are produced by the pancreas due to a 
malfunction of insulin-producing beta cells. T1DM was 
previously termed “insulin-dependent diabetes mellitus” 
(IDDM), or juvenile-onset diabetes, and it accounts for ~5-
10% of all diagnosed cases of diabetes. This disorder is 
lethal unless treatment with an exogenous supply of insulin 
is used to replace this crucial hormone. T2DM, which was 
previously termed non-insulin dependent diabetes mellitus 
(NIDDM), or adult-onset diabetes, accounts for about 90-
95% of all diagnosed cases [47, 48]. In T2DM, the pancreas 
functions normally to produce enough insulin but the cells of 
the body are resistant to it. T2DM is caused by insulin 
resistance in peripheral tissues and is most frequently 
associated with aging, a family history of diabetes, obesity 
and failure to exercise. Individuals with T2DM have 
hyperglycaemia and hyperinsulinaemia [49, 50].  
GLUCOSE TRIGGERS INSULIN SYNTHESIS AND 
SIGNALLING 
  Insulin is a powerful anabolic and anti-catabolic peptide 
secreted exclusively by beta cells in the islets of Langerhans. 
These cells accumulate in tiny groups scattered throughout 
the tissue of the pancreas. Insulin is composed of two chains 
of amino acids (aa): the 21 aa A chain and the 30 aa B chain. 
Both chains are linked together by two disulfide bridges. 
However, a third disulfide bridge exists within the A-chain, 
linking the 6
th and 11
th residues of the A-chain. Insulin action 
is mediated by the IR, a complex multi-subunit cell surface 
glycoprotein. Binding of insulin activates the intrinsic 
tyrosine kinase activity of the receptor, which is composed 
of a pair of -subunits and a pair of -subunits. These are 
distributed mainly in the cortex and hippocampus. Insulin 
binds to the -subunits and induces conformational changes 
that are transmitted to the -subunits. Subsequently, the -
subunits autophosphorylate and initiate a cascade of 
phosphorylation and dephosphorylation reactions [51, 52].  
  Glucose is transported into beta cells by GLUT2 (Type 2 
glucose transporters); it then undergoes the universal energy-
producing pathway (glycolytic pathway) and enters the 
respiratory cycle. This produces the high energy ATP 
molecule via oxidation in the mitochondria. The increase in 
the ATP:ADP ratio also increases the number of ATP-gated 
potassium channels (K
+) in the beta cell membrane, 
preventing K
+ ions from being shunted across the cell 
membrane (Fig. 2) [53]. The ensuing rise in positive charge 
inside the cell, due to increased concentration of K
+ ions, 
leads to a depolarisation of the cell. The net effect is the 
activation of voltage-gated calcium channels (Ca
2+), which 
transport calcium ions into the cell [54]. The brisk increase 
in intracellular Ca
2+  level causes the activation of 
phospholipase C (PLC), which cleaves membrane 
phospholipid phosphatidylinositol-4,5-biphosphate (PIP2) 
into inositol-1,4,5-triphosphate (IP3) and diacylglycerol 
(DAG). IP3 then binds to ‘receptor proteins’ in the 
membrane of the ER. This triggers a rise in the concentration 
of Ca
2+ in the cells and the subsequent activation (together 
with DAG) of protein kinase C (PKC) and finally the release 
of pre-synthesised insulin, which is stored in secretory 
vesicles. The Ca
2+ level also regulates the expression of the 
insulin gene via the cAMP response element binding protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). APP processing and A accumulation. APP is metabolised by two competing pathways, the non-pathogenic -secretase pathway 
that generates sAPP and the pathogenic -secretase pathway that generates sAPP. The -secretase and -secretase cleavage releases the p3 
peptides, whereas pathogenic -and -secretase cleavage gives rise to A40 and A42 peptide fragments. All carboxy-terminal fragments are 
substrates for -secretase, thus generating the APP intracellular domain (AICD) as well as the secreted peptides p3 and A. A then 
aggregates into oligomers and subsequently into fibrillary amyloid plaques.  32    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
(CREB). This mechanism of glucose action on insulin 
secretion is similar to that in the pancreas and the brain [55].  
GLUCOSE AND ITS TRANSPORT IN THE BRAIN 
  Glucose is an essential fuel for the body and its 
metabolism is crucial for the brain. Glucose is metabolised 
by glycolysis and oxidative breakdown in both astrocytes 
and neurons. Neurovascular and neurometabolic coupling 
help the brain to maintain an appropriate energy flow to 
neural tissues under conditions of increased neuronal 
activity. Glucose in the CNS is transported via facilitated 
diffusion. This is mediated by a certain glucose transporter 
family termed “GLUT”. These transporters are localised to 
the BBB, endothelial cells and cortical membranes. In the 
brain, GLUT1, GLUT2 and GLUT5 are expressed 
predominantly in a cell-specific manner [56-58]. Two forms 
of GLUT1 exist in the brain at different molecular weights 
(MW): 55 kDa and 45 kDa. The MW depends on the degree 
of glycosylation of GLUT1. The 55 kDa form is essentially 
localised to brain microvessels, choroid plexus and vascular 
endothelial cells, whereas the 45 kDa form is found 
predominantly in astrocytes [59, 60]. Although GLUT3 is 
considered specific to neurons, it has also been detected in 
brain astroglial cells, brain endothelial cells and other tissues 
such as the placenta, liver and kidney. GLUT5 is localised to 
microglial cells, the resident macrophages of the brain. It 
plays a pivotal role in the immune and inflammatory 
responses of the nervous system and can also be found in the 
brain endothelium.  Another member of the GLUT family, 
GLUT2, is selectively localised to astrocytes of discrete 
brain areas such as the hypothalamic and brain stem nuclei. 
These areas participate in the regulation of feeding behaviour 
and in the central control of insulin release. Other GLUT 
members that are selectively dispersed in the brain are the 
insulin-sensitive GLUT4 and GLUT8. GLUT4 is also found 
in the pituitary and the hypothalamus. However, GLUT8 is 
expressed only in the hippocampus, the cerebral cortex and 
the hypothalamus [61-63]. In actuality, glucose enters the 
brain through the 55 kDa GLUT1 transporters of the 
endothelial cells of the BBB. In astrocytes, glucose uptake is 
mediated by the 45 kDa GLUT1 transporters, whereas 
GLUT3 transporters mediate this process in neurons. Finally, 
GLUT5 has been found to mediate the uptake of an 
unidentified substrate into microglial cells [64]. 
INSULIN AND ITS RECEPTORS IN THE BRAIN 
  The most contentious feature of brain insulin research 
concerns the origin of insulin in the brain. Insulin in the 
brain basically originates from pancreatic -cells, but is also 
partially formed in pyramidal neurons such as those in the 
hippocampus, the prefrontal cortex, the entorhinal cortex and 
the olfactory bulb; however, it is not synthesized by glial 
cells. Insulin can enter circum ventricular regions that lack a 
BBB, and it can also cross the BBB via insulin transporter-
mediated active transport [65]. Insulin gene expression and 
synthesis have been demonstrated in both mature and 
immature mammalian neuronal cells, yet the consensus is 
that little or no insulin is produced in the CNS [66]. Insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Glucose triggers insulin synthesis and signalling. Insulin secretion in beta cells is triggered by rising blood glucose levels. 
Starting with the uptake of glucose by the GLUT2 transporter, the glycolytic phosphorylation of glucose causes an increase in the ATP:ADP 
ratio. This increase inactivates the K
+ channel that depolarises the membrane, causing the Ca
2+ channel to open up and allowing Ca
2+ ions to 
flow inward. The ensuing increase in levels of Ca
2+ ions leads to the exocytotic release of pre-synthesised insulin stored in vesicles. Finally, 
insulin is released from the storage vesicles.  Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    33 
acts as a mediator in the communication between the 
peripheral endocrine system and the brain via various steps 
of the neuroendocrine axis. The insulin receptor is a 
heterotetrameric tyrosine kinase receptor that undergoes 
dimerisation and tyrosine autophosphorylation upon binding 
insulin. Insulin receptors are widely distributed in the brain, 
with the highest densities in the olfactory bulb, the 
hypothalamus, the cerebral cortex and the hippocampus [67]. 
In the brain, insulin/insulin-like growth factor 1 (IGF1) and 
their cognate receptors regulate a multitude of processes 
such as glucose metabolism, neuronal differentiation, stem 
cell proliferation, cellular repair mechanisms and cognitive 
function [68, 69]. Increased concentration of peripheral 
insulin modulates BBB insulin transporters to regulate its 
transport into the brain [66, 70]. IGF1 is also synthesised 
locally in many tissues, including the brain. In contrast to 
insulin, IGF1 in the circulation and in tissues is bound to 
high affinity IGF binding proteins (IGFBPs) [71]. The 
receptor for IGF1 is structurally similar to the insulin 
receptor; both are tyrosine kinases that phosphorylate similar 
insulin receptor substrate proteins [72]. Glucose metabolism 
and insulin receptor mediated signal transduction control the 
activity of several enzymes involved in the generation of the 
APP derivative A and the phosphorylation of the Tau 
protein, the two hallmarks of AD. 
INSULIN/IGF1 SIGNALLING PATHWAYS AND AD 
Insulin/IGF1 Signalling in APP Processing 
  Impaired insulin and insulin-like growth factor 
expression and signaling mechanisms are found in AD and 
considered as type 3 diabetes [70, 73, 74]. Insulin and IGF1 
receptors are tyrosine kinases that mediate the 
phosphorylation of insulin receptor substrates (IRSs) 
including IRS1-4. Phosphorylated IRS proteins activate 
multiple signalling pathways that include PI3K and the 
extracellular signal-regulated kinase (ERK) cascades, which 
directly modulate various physiological processes [75]. PI3K 
is an important mediator of the metabolic signalling 
pathway. This kinase is a dimer composed of a 110-kDa 
catalytic subunit and a p55-kDa or p85-kDa regulatory 
subunit. Tyrosine-phosphorylated IRS associates with the 
two SH2 domains of the regulatory subunit p85, which in 
turn binds the catalytic subunit p110. PI3K is insulin 
regulated and activates protein kinase B (PKB), otherwise 
known as AKT. Activated PI3K also promotes the growth of 
cortical pyramidal neurons that play a key role in learning 
and memory [76, 77]. AKT then regulates the activity of the 
glycogen synthase kinase-3/ (GSK-3/). GSK-3 
contributes to the hyper-phosphorylation of Tau [78] and 
regulates the production of the APP derivative A, which is 
generated intracellularly in the ER/Golgi apparatus [79]. 
GSK-3 is also functionally important for regulating 
glycogen metabolism, cell cycle kinetics, proliferation, 
survival and cell migration. AKT inhibits GSK-3, which 
promotes cellular metabolism, proliferation and cell survival 
(Fig. 3). Simultaneous release of GSK-3 may promote the 
storage and misfolding of APP metabolites. The subsequent 
accumulation of A42 leads to neurite and neuronal 
degeneration [79]. 
  Transcription of the genes for insulin and IGF1 receptors 
is reduced in AD brains compared with controls [80, 81]. AD 
brains also demonstrate reduced expression of the IRS, IRS-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Insulin/IGF1 signalling pathways and AD. Insulin or IGF1 binds with its respective specific receptor sites to activate the IRS 
proteins that enter the PI3K and PKB/AKT pathways. These pathways cross the GSK-3 and thereby produce the Tau hyper-phosphorylation 
characteristic for AD. The alternative pathway leads to Shc, Grb2/SOS, Ras, Raf, MAPK activation and gene expression. The absence of 
IGF1 leads to decreased glucose uptake, decreased glycogen and protein synthesis, an increased level of AGEs, increased Tau 
phosphorylation and thus increased apoptosis.  34    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
associated PI3K, and activated AKT/PKB [82], suggesting 
downstream abnormalities in insulin/IGF intracellular 
signalling mechanisms. As mentioned earlier, activation or 
inhibition of these signalling mechanisms can influence the 
metabolism of APP and A. IGF1 also blocks A toxicity in 
primary cultures of hippocampal neurons. This inhibition of 
A toxicity occurs through the activation of ERK and 
AKT/PKB and the prevention of c-Jun N-terminal kinase 
(JNK) activation in a PI3K-dependent manner [74, 83]. 
Recent studies provide further support for PI3K as a 
modulator of APP trafficking and demonstrate that over-
activation of the insulin/IGF-1 signaling pathway may result 
in feedback inhibition of PI3K through IRS1 and reduced 
APP trafficking and A secretion [84]. In vivo, insulin/IGF1 
signalling is strongly neuroprotective in a variety of AD 
models. For example, IGF1 protects against mutant APP 
signalling and chronic subcutaneous infusion of IGF1 has 
been reported to reduce CNS A levels in aging rats and 
amyloid plaques in the AD transgenic mouse (Tg2576) 
model [85-87]. Indeed, IGF1R may activate a common 
signaling cascade that now seems to link aging to age-
associated pathologies of the brain [88]. A disturbed cross 
talk between IGF1 and AMP-activated protein kinase might 
be a possible cause that could underlie vascular dysfunctions 
observed in AD [89]. 
Insulin/IGF1 Signalling in Tau Phosphorylation 
Impaired insulin/IGF1 signalling results in the hyper-
phosphorylation of Tau due to reduced activation of 
PI3K/AKT and increased levels of GSK-3 activity (Fig. 3). 
Tau is normally phosphorylated by GSK-3 and 
dephosphorylated by the protein phosphatase PP2A [90, 91]. 
In addition, GSK-3 can be activated through the inhibition 
of insulin/IGF1 signalling via the Wnt pathway, which is not 
dependent on PI3K/AKT phosphorylation. Impairment of 
Wnt signalling mechanisms have been proposed as one key 
molecular abnormalities in AD [92]. Hyper-phosphorylated 
Tau fails to be transported into axons and instead 
accumulates and aggregates in neuronal perikarya, where it 
promotes oxidative stress that can cause cell death mediated 
by apoptosis, mitochondrial dysfunction or necrosis. 
Therefore, the decreased phosphorylation of GSK-3 
observed in NIRKO mice results in an increase in GSK-3 
activity and may cause elevated Tau phosphorylation [93]. 
Another study used a mouse model in which the disruption 
of IR tyrosine kinase signalling led to an accumulation of 
phosphorylated Tau in the hippocampus. ERK, mitogen-
activated protein kinase (MAPK) and cyclin-dependent 
kinase 5 (CDK-5) are important for the physiological 
phosphorylation of Tau protein, both of which are activated 
by insulin/IGF1 receptor. A deficit in insulin concentration 
increases the activity of GSK-3, which has been found to 
cause Tau hyper-phosphorylation and APP metabolism. This 
may suppress neuronal survival under neurodegenerative 
conditions [94-96]. 
DIABETIC COMPLICATIONS AND NEURODEGEN-
ERATION 
  Insulin resistance and hyperinsulinaemia are associated 
with elevated inflammatory markers and increase the risk of 
AD [97]. The hallmarks of insulin resistance include 
selective impairment of the PI3K intracellular signalling 
pathway in response to insulin, compensatory 
hyperinsulinaemia, elevated free fatty acids (FFA) and 
inflammation. PKC and DAG signalling pathways are 
affected during insulin resistance as well. PKC and DAG are 
intracellular signalling molecules that regulate vasculature 
through endothelial permeability and vasodilation. The PKC 
isozymes are a family of 12 related serine/threonine kinases 
whose normal function is to activate proteins and lipids that 
are essential for cell survival. PKC activation is a critical 
step in the pathway to diabetic microvascular complications 
[98]. This activation leads to changes in vascular 
permeability, the extracellular matrix (ECM) synthesis, 
cytokine synthesis, smooth muscle contraction and 
angiogenesis, as well as oxidative and osmolar stress, both of 
which are a consequence of the dysmetabolism of diabetes. 
Increased DAG and Ca
2+ promote the overactivation of 
PKC-. 
 PKC- over-activation is induced by hyperglycaemia or 
fatty acids through receptor-mediated activation by PLC. 
Increased PKC activity and disordered FFA metabolism 
have been implicated in the over-expression of the 
angiogenic vascular endothelial growth factor (VEGF), 
nuclear factor-kappa B (NF-B), transforming growth factor-
 (TGF-), endothelin-1 (ET-1), and intercellular adhesion 
molecules (ICAMs). It is also involved in the development 
of diabetic complications such as retinopathy, nephropathy 
and CD [99]. PKC- hyperactivity leads to increased 
vascular permeability, NO dysregulation, and increased 
leukocyte adhesion, and it is believed to be involved in cell 
proliferation, differentiation and apoptosis. Furthermore, 
PKC- hyperactivity in neural microvessels causes 
vasoconstriction. This may lead to decreased blood flow, 
resulting in hypoxia followed by nerve dysfunction in the 
brain. Additionally, PKC- activates MAPK, which 
subsequently phosphorylates transcription factors that are 
involved in angiogenesis as well as expression of stress-
related genes, JNK and heat shock proteins [100]. VEGF 
plays a critical role not only in angiogenesis but also in the 
development of the nervous system [101]. Diabetic animal 
models have shown high levels of PKC- in a number of 
tissues including nerves and endothelium. This may further 
accelerate the loss of nerve conduction [102]. 
  Elevated blood glucose may be directly toxic to nerves 
and intravenous infusions of glucose increase neuropathic 
pain [103]. Hyperglycaemia causes the activation of the 
polyol pathway, leading to the conversion of glucose into 
sorbitol by aldose reductase (Fig. 4). The accumulation of 
the organic osmolyte sorbitol leads to compensatory 
depletion of other intercellular osmolytes, such as 
myoinositol and taurine, which in turn leads to reduced 
Na
+/K
+  adenosine triphosphatase (ATPase) activity. The 
polyol pathway also generates fructose, which together with 
several other compounds such as glucose, glucose-6-
phosphate and galactose stimulates the non-enzymatic 
glycation reaction. This is another metabolic effect of 
hyperglycaemia. In this process, reduction of sugars forms 
reversible glycosylation products with proteins, some of 
which rearrange to form irreversible AGEs [104]. These 
AGEs can crosslink proteins, including neurofilaments and 
basement membrane components. Vascular abnormalities 
observed in patients with diabetic polyneuropathy include 
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endothelial dysfunction, increased expression of endothelin 
and alterations in VEGF expression. Pathologic studies of 
proximal and distal segments of nerves in diabetic 
polyneuropathy have shown multifocal fibre loss along the 
length of the nerves, suggesting ischaemia as a pathogenetic 
contributor [105]. Vascular and metabolic mechanisms likely 
interact; hyperglycaemia has a number of deleterious effects 
on blood vessels [106]. Vessel wall matrix proteins may be 
affected by non-enzymatic glycation. Hyperglycaemia can 
lead to increased oxidative stress with the production of 
superoxides and NO. These substances can interact, leading 
to protein nitration or nitrosylation, lipid peroxidation, DNA 
damage and endothelial and neuronal cell death. Superoxides 
also lead to the activation of PKC, which induces 
vasoconstriction and reduces neuronal blood flow [107].  
  Diabetic retinopathy (DR) is the most specific 
microvascular complication and one of the leading causes of 
visual impairment in diabetic patients. DR complications 
result from functional and morphological alterations of 
retinal capillaries, increased permeability to albumin and 
macromolecules, vascular dysfunction, loss of pericytes and 
basement membrane thickening. The classic risk factors for 
diabetic retinopathy are hyperglycaemia, hypertension and 
hyperlipidaemia. These cardiovascular risk factors are 
important for both the initial development of diabetic 
retinopathy and the subsequent progression to advanced 
retinopathy [108]. 
  Diabetic nephropathy (DN) is a chronic kidney disease 
characterised by abnormal deposits of matrix material in the 
glomerular mesangium, leading to glomerulosclerosis. This 
disorder is also known as intercapillary glomerulonephritis 
and is described histopathologically by axonal degeneration, 
demyelination and atrophy, in association with failed axonal 
regeneration, remyelination and synaptogenesis [109, 110]. 
DN typically affects the network of tiny blood vessels in the 
glomerulus, which is necessary for the filtration of blood. 
The pathophysiology of DN suggests that complex 
interactions exist between multiple pathways. These include 
abnormalities in glucose transport mechanisms, increased 
activity of specific intracellular metabolic pathways, 
activation of PKC isoforms, formation of reactive oxygen 
species (ROS) and increased production of AGEs. Altered 
activity of a variety of growth factors and cytokines may be 
critical factors in the development of microvascular diabetic 
complications including nephropathy [111, 112].  
ENDOTHELIAL DYSFUNCTION IS A BRIDGE 
BETWEEN T2DM AND CARDIOVASCULAR DIS-
EASES 
  The endothelium is a single layer of cells that lines all 
vessels in the body, including conduit vessels, resistance 
vessels, pre-capillary arterioles and capillaries. By virtue of 
its direct contact with the circulating blood, the endothelial 
layer provides a critical interface between the elements of 
blood and the tissues. The function of each vessel and the 
role of its respective endothelium vary according to its 
location in the body. In the conduit vessels, which include 
larger arteries such as the aorta and the carotid/coronary/ 
brachial/femoral arteries, a healthy endothelium provides a 
smooth, quiescent surface that limits the activation of 
clotting and proinflammatory factors. This endothelium also 
blocks the transfer of lipid particles into the arterial wall, 
inhibits the release of chemokines/cytokines/growth factors 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Diabetic complications and neurodegeneration. In diabetes, hyperglycaemia leads to the formation of DAG, AGEs and oxidative 
stress. These factors enter the PKC- pathway and produce microvascular damage characteristic of diabetic cardiomyopathy, diabetic 
neuropathy and diabetic nephropathy.  36    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
and prevents adhesion of platelets and monocytes to the 
vascular endothelium. In the resistance vessels, endothelial 
cells (ECs) help to regulate blood flow and systemic blood 
pressure, whereas in the precapillary arterioles, they play a 
role in the transport and disposal of waste products of 
metabolism as well as the distribution of nutrients and 
hormones such as glucose, fat and insulin. ECs protect blood 
vessels not only by providing a mechanical lining, but also 
by controlling vascular tone, inflammation, and thrombosis 
[113]. EC production of NO and prostacyclin causes 
vasodilatation, whereas ET-1 mediates vasoconstriction 
[114]. Inflammatory molecules produced by ECs include 
interleukin-1 (IL-1), IL-6, IL-18, tumour necrosis factor- 
(TNF-), monocyte chemoattractant protein-1 (MCP-1) and 
a number of adhesion molecules. Compelling evidence 
supports endothelial dysfunction as a key early event in the 
pathogenesis of atherosclerosis. The term endothelial 
dysfunction encompasses several potential abnormalities; the 
most extensively studied anomalous characteristic is a 
reduction in the bioavailability of NO. NO is an 
antiatherosclerotic signalling molecule released by the 
vascular endothelium that has potent vasodilatory, anti-
inflammatory, anti-proliferative, anti-oxidant, and anti-
platelet effects. NO bioavailability is reduced in 
atherosclerotic vessels before vascular structural changes 
occur. Impaired NO-dependent vasodilatation is a predictor 
of future cardiac events and the development of coronary 
artery atherosclerosis [115-117].  
  In ECs, insulin increases peripheral vascular blood flow 
by simulating NO production. FFAs inhibit the insulin-
induced increase in peripheral venous NO and peripheral 
blood flow via two pathways. As illustrated (Fig. 5), the first 
pathway involves reduction of the tyrosine phosphorylation 
of IRS-1/2. FFAs inhibit the PI3K/AKT pathway, which, 
aside from controlling insulin-stimulated glucose uptake, is 
also needed to stimulate endothelial NOS (e-NOS). Thus, the 
production of NO in ECs is inhibited. The second inhibitory 
pathway involves FFA activation of NADPH oxidase in a 
DAG/PKC-dependent manner. Activation of NADPH 
oxidase leads to the production of ROS, which results in the 
destruction of NO [118, 119]. The lipid metabolites activate 
serine kinases such as PKC and inhibitory B kinase (IB), 
which regulate the activation of nuclear factor-B (NF-B), 
a transcription factor associated with inflammation. The 
aberrant regulation of NF-B is associated with a number of 
chronic diseases including diabetes and atherosclerosis 
[120]. NF-B is activated through a common pathway that 
involves the phosphorylation-induced, proteasome-mediated 
degradation of the inhibitory subunit IB. IB is 
phosphorylated by the upstream serine kinase IKK, which is 
phosphorylated and activated by additional upstream serine 
kinases. Elevated plasma FFA levels also produce low-grade 
inflammation in skeletal muscle and liver via activation of 
the NF-B pathway. This results in the synthesis and release 
of pro-inflammatory and pro-atherogenic cytokines. 
Likewise, palmitate activates IKK and JNK, thereby 
increasing serine phosphorylation of IRS and decreasing 
insulin stimulated production of NO. In healthy people, 
insulin infusion results in the release of both NO and ET-1 in 
adequate concentrations to ensure an appropriate balance for 
maintaining vascular tone. In contrast, in diabetic patients 
there is an increased production of ET-1 that creates a 
vasoconstrictive environment to further impair endothelial 
function [121]. At the molecular level, insulin exerts its 
effects through the PI3K or MAPK pathways. In insulin 
resistance states, the activation of the PI3K pathway is 
inhibited, whereas the activation of the MAPK pathway is 
largely intact. The net result is a reduction in vasodilatation 
and an increase in vasoconstriction, inflammation, and 
thrombosis that explains much of the increased 
atherothrombotic risk in diabetic patients [122]. The 
accumulation of AGE products in diabetes impairs EC 
function in animal models. Furthermore, AGE products 
promote vascular inflammation and induce ROS 
accumulation, and both of these processes contribute to 
endothelial dysfunction via inhibition of NO production. In 
addition, acute hyperglycaemia can result in NO reduction 
and attenuation of endothelium-dependent vasodilatation. 
Therefore, vascular endothelial dysfunction may occur at any 
or all levels in the arterial system and contributes to the 
development and progression of atherosclerosis by favouring 
coagulation, cell adhesion, and inflammation. This is 
achieved by promotion of inappropriate vasoconstriction or 
vasodilation and by enhancement of transendothelial 
transport of atherogenic lipoproteins [123]. 
ROLE OF CYTOKINES IN NEUROINFLAMMATION 
AND AD  
  Cytokines also play critical roles in the development and 
progression of AD. Cells associated with extracellular 
plaques within the brains of AD patients can produce a 
variety of cytokines and other related proteins that can 
ultimately influence plaque and tangle formation. 
Additionally, A itself can stimulate microglia and 
astrocytes to secrete pro-inflammatory cytokines, 
chemokines and reactive ROS, which can lead to neuronal 
damage [16]. The overproduced cytokines generate a 
“vicious circle” leading to irreversible synaptic loss and 
consequently to behaviour alterations. Five major cytokines 
have been extensively studied in relation to AD onset or 
progression. Four are pro-inflammatory cytokines: IL-1, IL-
1, TNF- and IL-6. TGF- mainly has an anti-inflammatory 
role [124]. TNF- is a critical component of the brain's 
immune system. Normally, TNF finely regulates the 
transmission of neural impulses in the brain. Excess TNF- 
has been documented in the cerebrospinal fluid of patients 
with AD [125]. In addition to being secreted by astroglia and 
microglia, circulating peripheral TNF- can diffuse through 
the BBB and access brain cells. 
  During neuropathologic and neurodegenerative 
conditions, the level of brain TNF- increases dramatically, 
suggesting a significant role of this cytokine in these 
processes. Whereas the pro-inflammatory effects of TNF- 
are most relevant at later stages, TNF- also has 
neuroprotective and regenerative functions during the early 
processes of neurodegenerative diseases [126]. TNF- has 
both neurotoxic and neuroprotective effects mediated, 
respectively, by two receptor subtypes: TNF receptors 1 and 
2 (TNFR1 and TNFR2). These two receptors trigger the 
activation of NF-B. Most neuroprotective roles of TNF- 
are mediated via conscription of NF-B. In addition to direct 
IKK mediated activation, NF-B can also be activated via 
pro survival kinases such as AKT/PKB. Activated NF-B 
dimers enter the nucleus and influence the expression of a Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    37 
complex array of genes constituting the neuronal response to 
various neurodegenerative disorders. In particular, neuronal 
NF-B is proposed to be neuroprotective in nature [127]. In 
contrast, neurotoxic TNF- inhibits the transport of A from 
the brain to the periphery, and elevated TNF- levels may 
increase brain accumulation of A [86]. Paradoxically, 
TNFR1 contains a death receptor domain and has been 
implicated in pro-apoptotic events, whereas TNFR2 
promotes cell survival [128]. Increased levels of TNFR1 and 
decreased levels of TNFR2 have been observed in AD brains 
and in peripheral lymphocytes from older adults compared 
with younger adults though others say that the receptors may 
not play a major role in the development of AD [129-131]. 
A42 interacts with inflammatory agents in a cyclically 
reinforcing manner, such that A elevations increase levels 
of pro-inflammatory cytokines [132]. In vitro, soluble A 
oligomers rapidly increase the levels of IL-1 and TNF-. 
Conversely, IL-6 and IL-1 can regulate the processing of 
APP, from which A is derived, and increase the production 
of A42 [133].  
ROLE OF ADVANCED GLYCATION END PRO-
DUCTS (AGES) IN DIABETIC VASCULAR DISEASES 
AND AD 
  Glucose and other reducing sugars react non-
enzymatically with protein amino groups to initiate a post-
translational modification process known as non-enzymatic 
glycosylation. This reaction proceeds from reversible Schiff 
bases to stable, covalently bonded Amadori rearrangement 
products. Once formed, the Amadori products undergo 
further chemical rearrangement reactions to form irreversibly 
bound AGEs, which play a significant role in the 
pathogenesis of the chronic complications of diabetes 
mellitus (Fig. 6) [134]. AGEs are a heterogeneous group of 
structures; those that have already been identified include 
pyrraline, pentosidine, crossline, and carboxymethyl lysine 
(CML). These biomolecules are found both inside and 
outside of cells. Intracellularly, AGEs generally alter 
functions and cellular transport. However, AGEs that are 
present extracellularly disrupt cellular adhesion and activate 
the AGE receptor (RAGE). AGE is used for a broad range of 
glycation processes (also called the “Maillard reaction”). 
Hence, hyperglycaemia leads to the formation of AGEs in 
high concentrations. AGEs have been implicated in the 
development of oxidative stress, as well as in T2DM. They 
also play a role in atherosclerosis and renal insufficiency 
during aging [135]. RAGE is a member of the 
immunoglobulin superfamily of cell surface molecules and is 
expressed in a variety of cell types, including ECs, pericytes, 
mesangial cells, neurons and glia. The receptor-mediated 
reactions may further contribute to neuronal degeneration. 
AGE formation causes increased stiffness in the 
cardiovascular system, leading to high blood pressure and 
modification of functionally important proteins like tubulin 
and ATPases. The formation of AGEs is also associated with 
the increased production of ROS. ROS is also linked to the 
pathophysiological model of non-enzymatic glycation effects 
on oxidative stress. The binding of RAGE by AGEs is 
capable of mediating inflammatory responses and oxidative 
stress and leads to diabetic vascular complications [136, 
137]. AGEs cause many effects, such as blockage of 
transport through cell membranes, blockage of protein 
synthesis, reduction of tissue strength and elasticity and 
fragmentation of molecules that include DNA [138]. AGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Endothelial dysfunction is a bridge between T2DM and cardiovascular diseases. Increased levels of FFA and DAG trigger a 
serine/threonine kinase cascade, ultimately inducing serine/threonine phosphorylation of critical IRS-1 sites and thereby inhibiting IRS-1 
binding and the activation of PI3-kinase, which results in reduced insulin-stimulated glucose transport.  38    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
immunoreactivity is associated with pathologic hallmarks of 
AD (NFTs and NPs), cortical neurons, microglia, astrocytes 
and blood vessels in AD brains [139, 140]. The most 
prominent species of AGEs in tissues, N-epsilon-CML 
adducts, are found at their highest levels in the hippocampus. 
Levels of CML expression in neurons are correlated with 
NFT pathology. Interestingly, AD patients with T2DM 
showed enhanced formation of CML, possibly owing to the 
increased levels of glucose and enhanced oxidative stress 
[136]. Astrocytes were the major brain cell type shown to 
contain AGE products by immunohistochemical techniques 
that involved antibody reaction with AGEs [141]. AGE-
immunoreactive astrocytes are also associated with mature 
amyloid plaques and express elevated neuronal NOS 
(nNOS). In cultured astrocytes, AGEs increase the release of 
IL-1, TNF- and NO. In a murine microglial cell line, 
RAGE was shown to be involved in AGE-mediated 
generation of IL-6, TNF- and NO. AGEs, in combination 
with endogenous NO, increased ROS production, resulting 
in caspase-3-dependent apoptosis in SH-SY5Y 
neuroblastoma cells [142].  
  During normal aging, AGEs accumulate in the brain; this 
accumulation is implicated in the pathogenesis of AD. AGE 
products bind to RAGE, which is present in neurons and 
binds to amyloidogenic APP derivative A [143]. A 
interaction with RAGE on ECs leads to the transport of A 
across the BBB and the expression of pro-inflammatory 
cytokines in those cells [144]. It has also been shown that 
RAGE stimulates functional BACE1 expression through 
nuclear factor of activated T-cells 1 (NFAT1) activation, 
resulting in more A production and deposition in the brain 
[145]. The deposition of A peptides is thought to be an 
early and causative event in the pathogenesis of AD and 
increases markedly during the progression of the disease, 
leading in turn to the generation of NFTs and finally 
neuronal death [136, 146].  
CHOLESTEROL SYNTHESIS, TRANSPORT AND 
METABOLISM IN THE BRAIN 
  Cholesterol is a necessary component of all cell 
membranes and is important both as a structural component 
and as a modulator of cell membrane fluidity. Cholesterol is 
a waxy, fat-like compound that belongs to a class of 
molecules called steroids. It maintains the integrity of cell 
membranes and functions to resist changes in temperature 
and to protect and insulate nerve fibres. It is also involved in 
the formation of sex hormones (progesterone, testosterone, 
estradiol, cortisol) and the production of bile salts, which 
help to digest food. Furthermore, it is converted into vitamin 
D in the skin when exposed to sunlight. Cholesterol is 
synthesised in the liver and the brain and can also be 
obtained through a diet of animal products [147]. It is highly 
enriched in the brain in comparison with other tissues. In the 
blood, it is carried on lipoproteins that are classified into 
chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density 
lipoproteins (LDL) and high-density lipoproteins (HDL) 
[148].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Formation of advanced glycation end products (AGEs) in diabetic vascular diseases and AD. Glucose enters the cell and the 
glycolytic and tricarboxylic acid (TCA) pathways and eventually produces ATP and amino acids. AGEs are formed from reactions between 
carbohydrates and proteins. Subsequently, AGEs bind to the RAGE receptors. The RAGE receptor helps A to cross the BBB, after which 
A forms neuritic plaques (NP).  Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    39 
  The majority of cholesterol present in the brain is 
synthesised in the CNS. The brain is the most cholesterol-
rich organ in the body and contains about 25% of the total 
body cholesterol. Cholesterol synthesis begins with the 
transport of acetyl-CoA from the mitochondria to the cytosol 
[149]. For every reversal of the thiolase reaction, two 
molecules of acetyl-CoA are condensed to form acetoacetyl-
CoA. Acetoacetyl-CoA and a third molecule of acetyl-CoA 
are converted to HMG-CoA with the aid of HMG-CoA 
synthase (Fig. 7). HMG-CoA is converted to mevalonate by 
HMG-CoA reductase. Mevalonate is then activated by three 
successive phosphorylations, yielding mevalonate pyrophos-
phate (MPP). In addition to activating mevalonate, these 
phosphorylations maintain solubility. After phosphorylation, 
ATP-dependent decarboxylation yields isopentenyl 
pyrophosphate (IPP), an activated isoprenoid molecule. IPP 
is in equilibrium with its isomer, dimethylallyl pyrophos-
phate (DMPP). One molecule of IPP is condensed with one 
molecule of DMPP to generate geranyl pyrophosphate 
(GPP). GPP is further condensed with another IPP molecule 
to yield farnesyl pyrophosphate (FPP). Thereafter, the 
NADPH-requiring enzyme squalene synthase catalyses the 
head-to-tail condensation of two molecules of FPP, yielding 
squalene (squalene synthase is also tightly associated with 
the ER). Squalene then undergoes a two step cyclisation to 
yield inosterol. Finally, the inosterol is converted into 
cholesterol [147]. 
  Transport of cholesterol from the peripheral circulation 
into the brain is prevented by an intact BBB. In the CNS, 
essentially all cholesterol is unesterified and the majority of 
cholesterol is localised in the myelin sheaths formed by 
oligodendrocytes. The remaining brain cholesterol is found 
in neurons, glial cells and extracellular proteins. These pools 
of cholesterol participate in cholesterol homeostasis of the 
CNS [150, 151]. Both dietary cholesterol and cholesterol that 
are synthesised de novo are transported through the 
circulation in lipoprotein particles [152]. The same is true of 
cholesterol esters (CEs), the form in which cholesterol is 
stored in cells. The synthesis and utilisation of cholesterol 
must be tightly regulated in order to prevent over-
accumulation and abnormal deposition within the body. 
Cholesterol plays an important part in the regulation of A 
production, with high cholesterol levels being linked to 
increased A generation and deposition [153]. Abnormalities 
in the cholesterol metabolism contribute to the development 
of atherosclerosis, heart disease and AD [154, 155].  
  Cholesterol is insoluble in the blood and therefore needs 
carriers known as lipoproteins to aid in its transportation to 
cells. Astrocytes not only synthesise but also internalise and 
recycle cholesterol that has been released from degenerating 
nerve terminals. Astrocytes have the highest capacity to 
produce ApoE. ApoE binds cholesterol and acts as a ligand 
for cell surface-lipoprotein receptors such as LDL-receptor-
related proteins (LRP), illustrated in (Fig. 8). ApoE is one of 
the major apolipoproteins found in the plasma. There are 
spherical and discoidal shaped HDL particles. Under normal 
conditions, this is an important protein for cholesterol 
function in the brain and within the CNS; it has the 
important metabolic function of regulating lipid transport 
into neurons and clearing cholesterol from ECM [156]. 
Neurons and glial cells contain LRP receptors, which are 
large endocytic membrane receptors that can bind and 
internalise the ApoE-cholesterol phospholipid complex and 
then fuse with lysosomes. Lysosomes are vesicles that 
contain the necessary hydrolytic enzymes to allow the 
intracellular release of free cholesterol (FC). The ATP-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Cholesterol synthesis in the brain. Acetyl CoA and acetoacetyl CoA combine to form HMG CoA. The conversion of HMG CoA 
to mevalonate by HMG CoA reductase is the main regulatory step in the overall pathway. Statins are inhibitors of HMG CoA reductase and 
inhibit the cholesterol biosynthesis pathway. 40    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
binding cassette (ABC) transporter ABCA1 functions to 
secrete cholesterol from astrocytes and is an important 
regulator of cholesterol metabolism. In the brain, ABCA1 is 
also important for cholesterol trafficking, and its expression 
in cerebral endothelial cells can be stimulated by 24-
hydroxycholesterol, thus suggesting a role in the removal of 
excess brain cholesterol [157].  
  ABC transporters, particularly the ABCA1 transporter 
expressed in astrocytes, may also be of importance for 
shuttling cholesterol from glial cells to neurons. After 
cholesterol is synthesised in astrocytes, it is released through 
ABCA1 and packaged into lipoprotein particles resembling 
HDL, which in turn are then taken up into neurons through 
the recognition of ApoE by a variety of lipoprotein receptors 
such as LDLR, LRP and the ApoE receptor. The cholesterol 
is then oxidised into 24-hydroxycholesterol and 27-
hydroxycholesterol with the help of the enzymes CYP46 and 
CYP27. The 24-hydroxycholesterol is made by neurons 
within the brain [158-160]. In contrast, 27-hydroxycholes-
terol is produced by many cells, including neurons and 
oligodendrocytes. Cholesterol 24-hydroxylase, encoded by 
the CYP46 gene on chromosome 14, is expressed almost 
exclusively in the brain; only very low levels of its mRNA 
are found in other tissues such as the liver or testis. In the 
brain, CYP46 is expressed at especially high levels in 
neurons found in the cortex, hippocampus, dentate gyrus, 
thalamus and cerebellar Purkinje cells; however it does not 
appear to be expressed in glia [161]. CYP46 is a member of 
the cytochrome P450 family and is responsible for the 
catabolism of nearly all CNS cholesterol to 24-
hydroxycholesterol [162]. A portion of the FC reacts with 
CYP46 and is converted into 24-hydroxycholesterol in 
neurons, which can then re-enter the astrocytes for the 
recycling of cholesterol. The remaining excess cholesterol 
crosses the BBB and enters into the plasma, where it is 
eventually delivered to the liver for excretion into bile [163]. 
APOE AND AD  
  ApoE protein functions to maintain the synaptic integrity 
of neurons by stabilising the neuronal cytoskeleton, 
regulating intracellular Ca
2+ levels and regulating the 
interaction among neurons, ECM and cholesterol. The 
largest production of ApoE is found in the liver, followed by 
the brain. In the brain, ApoE is predominantly secreted by 
astrocytes and microglia [164]. Abundant experimental 
studies have shown that ApoE influences the majority of the 
AD pathological processes such as A generation or 
deposition, NFT formation, neuronal survival, lipid 
homeostasis and intracellular signalling [165]. There are 
three common human isoforms, namely ApoE2, ApoE3 and 
ApoE4, which arise from alleles E2, E3 and E4, respectively. 
ApoE3 is the most common isoform in the general 
population (77-78 %), while ApoE2 is found in only 7-8 % 
and ApoE4 is found in 14-16 % of individuals. ApoE4 is the 
strongest known risk factor for the development of SAD. 
The isoforms of ApoE influence Ca
2+ channels differentially, 
resulting in different concentrations of free intracellular Ca
2+. 
ApoE is also involved in various signalling pathways that 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (8). Cholesterol transport and metabolism in the brain. Cholesterol is mainly generated in astrocytes and is then transported to 
neurons. Cholesterol and ApoE are synthesised by the astrocytes and form the lipoprotein compound. These lipoproteins enter neurons 
through the neuronal surface receptors of the LDL-receptor related protein (LRP). Upon neuronal entry, the lysosome reacts with the 
lipoprotein and releases the free cholesterol from the neuron. Some of the free cholesterol reacts with the Cyp46 enzyme and forms the 24-
hydroxycholesterol. The 24-hydroxycholesterol is then released from the neuron to enter the astrocytes and to be reconverted into 
cholesterol. The remaining free cholesterol released from neurons crosses the BBB into the peripheral blood circulation. Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    41 
coincide with the signalling pathways relevant to AD [166]. 
These pathways also affect the activities of kinases such as 
PKC, GSK-3, PKB/AKT, ERK, and JNK, as well as the 
transcriptional activity of CREB. The ApoE4 allele has also 
been associated with familial hypercholesterolaemia. The 
direct effect of hypercholesterolaemia on ApoE levels in the 
brain leads to an accumulation of A. Neuronal ApoE 
receptors may also have a number of roles in APP trafficking 
and processing of A clearance [167]. Moreover, ApoE4 has 
been found to enhance the synthesis of A by promoting 
endocytotic recycling of APP. Findings obtained with the 
transgenic mouse model expressing human APPV717+/- 
(PDAPP mice) suggest that ApoE4 contributes to the 
deposition of A [168]. Another in vivo study in transgenic 
mice showed that carboxy-terminal truncated ApoE 
stimulates Tau phosphorylation and intracellular formation 
of NFTs [169].  
CHOLESTEROL AND APP PROCESSING 
  It has been shown that cholesterol accumulates in the 
dense cores of amyloid plaques. As a component of the cell 
membrane, cholesterol plays a major role in the metabolism 
of the single transmembrane protein APP and thus in the 
production of A [170]. Cholesterol is a major constituent of 
lipid rafts, together with sphingolipids (sphingomyelin and 
glycosphingolipids) and glycosylphosphatidylinositol (GPI)-
linked proteins. As several transmembrane receptors and 
cytoplasmic signalling molecules have been shown to 
concentrate to lipid rafts, they are considered functional hot 
spots of the plasma membrane. Lipid rafts are assembled in 
the Golgi complex and are constantly endocytosed. These 
lipid rafts appear to promote the accumulation of A and the 
initiation of A aggregation [171, 172]. Increased cholesterol 
levels may lead to elevated membrane cholesterol, which 
would cause a change in membrane fluidity and lead to 
increased APP processing and A production. In vitro 
studies suggest that increased plasma membrane fluidity may 
enhance APP/-secretase interactions and -secretase 
enzymatic activity. In contrast, rigid cholesterol-enriched 
membranes may reduce APP/-secretase interactions and 
promote  - and - secretase processing. The -secretase 
activity has been identified in cholesterol- and sphingolipid-
rich membrane microdomains known as lipid rafts. 
Cholesterol loading increases -secretase activity and results 
in enhanced release of amyloidogenic A  in vitro and in 
vivo. In transgenic mice over-expressing APP, a high 
cholesterol diet led to an increase in A and NPs and a 
decrease in sAPP [173-175]. 
  In addition to the effect of cholesterol on membrane lipid 
ordering, sub-cellular distribution of cholesterol also 
regulates the proteolytic processing of APP [176, 177]. 
Unprocessed, mature APP is transported to the plasma 
membrane, where it undergoes further cholesterol-dependent 
processing. Partially matured APP is transported to the Golgi 
complex, where it completes maturation and is finally 
transported to the plasma membrane (Fig. 9). APP 
processing is thought to occur mostly in the trans-Golgi 
network, the plasma membrane, and the endosomes. In 
addition, A may be generated in the endo/lysosomal system 
from endocytosed APP. Intracellular cholesterol plays a 
critical role in A formation by directing the association of 
-secretase with APP. Low intracellular cholesterol favours 
the processing of APP through the non-amyloidogenic 
pathway, leading to decreased A deposition. Newly 
synthesised APP is N-glycosylated in the ER, the site of 
cholesterol esterification and hydroxylation. - and -
secretase activities can be found in newly assembled 
cholesterol/sphingolipid-rich membrane microdomains in the 
Golgi [175, 178, 179]. 
  The newly generated A  is either released to the 
extracellular space or remains associated with the plasma 
membrane and lipid raft structures. Binding of A  to the 
cholesterol/sphingolipid-rich membrane microdomains (lipid 
rafts) strongly favours A aggregation [180]. Excess 
unesterified cholesterol in the plasma membrane and ER, as 
well as mitochondria-derived oxysterols, is loaded onto 
extracellular lipid acceptors such as ApoE by ABCA1. 
Monomeric A  can bind to numerous molecules in the 
extracellular space. Binding of ApoE to A  regulates not 
only the aggregation but also the cellular uptake of A. 
ApoE-A complexes are taken up by the cells through 
receptor-mediated endocytosis mediated by LRP and LDLR. 
Lipoprotein-bound cholesteryl esters are hydrolysed in the 
endo/lysosomal system, and cholesterol is transported 
through Niemann-Pick disease, type 1 (NPC1)-containing 
compartment to the ER and Golgi. Endocytosed A also has 
access to other subcellular compartments through the 
vesicular transport system [181, 182]. 
NGF AND THE HEART 
  Neurotrophins (NTs) are small, highly basic proteins that 
are essential in the nervous system. They are capable of 
promoting neuronal cell survival or cell death depending on 
the environment. Alterations in the NT levels may underlie 
several medical conditions including pain, depression and 
obesity. Levels are also altered in disorders of nerve 
regeneration, learning and memory [183]. NTs have four 
distinct members: NGF, brain-derived neurotrophic factor 
(BDNF), NT-3 and NT-4/5. These NTs activate a family of 
receptor proteins, the TRK receptors. TRKA is primarily a 
receptor for NGF, TRKB is a receptor for BDNF and NT-
4/5, and TRKC is the specific receptor for NT-3. In addition 
to these specific receptors, all NTs bind to the p75NTR, a 
member of the TNFR superfamily [184]. 
  NGF was the first nerve growth, survival and 
differentiation factor discovered, and it plays a crucial role in 
the sympathetic and sensory nervous systems. It regulates 
proliferation, differentiation and survival of various cell 
types of both the CNS and the PNS but also of cells of 
hematopoietic origin [17]. NGF signalling is mediated via 
binding to high and low affinity receptors. The high affinity 
receptor is TRKA, which transmits its signal via an internal 
tyrosine-kinase domain. The heart is innervated by 
sympathetic, parasympathetic and sensory nerve fibres 
expressing TRKA, which, together with the CNS, regulate 
cardiac functions. The efferent sympathetic and 
parasympathetic nervous system mediates the opposing 
neuronal regulation for inotropy and chronotropy of heart 
performance. NGF plays an important role in the 
maintenance and survival of such sympathetic neurons and a 
subset of sensory neurons during and after CNS and PNS 
development, although the survival of sensory neurons 
becomes independent of NGF in mature organisms [185]. 42    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
  NGF in the sympathetic nervous system has been 
considered to function as a target-derived survival factor that 
is supplied in limited quantities by target organs, such as the 
heart, to regulate the final number of neurons and density of 
innervation [186]. In the NGF-null mouse, sympathetic 
ganglia are not present [187]. Conversely, cardiac-specific 
NGF over-expression in the mouse causes increased 
sympathetic innervation density and increased levels of 
norepinephrine stored in the dysfunctional heart [188, 189]. 
An influence of NGF on the sympathetic nervous system is 
also evident in adult animals. Injection of NGF into the left 
stellate ganglion over several weeks in dogs leads to 
pronounced sympathetic neuronal growth and nerve 
sprouting in the heart [190].  
  Myocardial NGF and sympathetic nerves of the heart 
appear to be linked in more ways than just neural support 
provided by the NGF. Once synaptic connections are 
established, NGF can potentiate synaptic transmission 
between sympathetic neurons and cardiac myocytes  [191]. 
Modulation of these sympathetic synapses by NGF is acute 
and reversible and proves that synaptic potentiation works 
through a presynaptic mechanism. In addition to acute 
modulatory effects on synaptic efficacy, it has also been 
demonstrated that NGF produces a long-term enhancement 
of synaptic transmission of sympathetic neurons and cardiac 
myocytes [192]. Moreover, there is evidence of feedback 
inhibition of cardiac myocyte production of NGF at high 
levels of norepinephrine. The release of NGF by cultured 
cardiac myocytes is inhibited by norepinephrine, and chronic 
intravenous infusion of norepinephrine in dogs reduces 
myocardial NGF content [193]. High sympathetic tone in an 
innervated organ presumably inhibits its NGF production. 
This concept has been invoked to explain the concurrence in 
failing hearts of high sympathetic nerve firing rates, low 
NGF content and sympathetic neuronal rarefaction. 
Treatment of co-cultures of sympathetic neurons and cardiac 
myocytes with NGF, to preferentially activate neuronal 
TRKA, promotes the release of norepinephrine and increases 
the myocyte beat rate by fourfold [187]. In contrast, 
treatment with BDNF activates neuronal p75NTR, inducing 
the release of ACh and significantly slowing the rate of 
myocyte contraction [194]. These observations suggest that 
local secretion of NGF from cardiac myocytes and BDNF 
from the surrounding vasculature can rapidly exert opposing 
presynaptic actions to regulate heart rate and contractility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (9). Cholesterol and APP processing. Cholesterol plays a central role in APP metabolism and A synthesis. APP metabolism starts in 
the ER and then enters the Golgi complex and the plasma membrane. In the plasma membrane, A is released from APP. The free A binds 
with membrane-associated cholesterol, ultimately resulting in A aggregation. The remaining free A binds with ApoE and the cholesterol 
complex to re-enter the cell through the LRP receptor system. This ApoE-A complex is degraded by lysosome enzymes to release the free 
cholesterol and A.  Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    43 
Thus, strategies to interfere with NGF-mediated TRKA 
activation and BDNF-mediated p75NTR activation may 
prove beneficial in reducing sympathetic neuron sprouting 
and norepinephrine release [195-197].  
  In congestive heart failure, NGF levels in the heart 
decrease as plasma norepinephrine levels rise; 
concomitantly, ET-1 plasma levels rise as well. However, it 
is still not clear how these changes are interrelated. 
Additionally, a recent report suggests that ET-1 over-
expression in the adult mouse heart leads to dilated 
cardiomyopathy and death [198]. The complex interactions 
between myocytes and nerves in pathologic states provide 
insights into the disappointing results of ET-1 blockade in 
congestive heart failure and yield new pharmacologic targets 
for the future [199]. 
  Thus, these studies indicate that NGF is involved in the 
regulation of myocardial performance and contributes to the 
maintenance of circulatory stability and cardiovascular 
homeostasis. They also indicate that acute coronary 
syndrome, atherosclerotic coronary arteries and ischaemic 
myocardium are characterised by altered circulating levels of 
NGF [200]. Furthermore, direct gene transfer of NGF into 
diabetic rat hearts improves silent myocardial ischaemia. 
Therefore, NGF-TRKA signalling might be a potential 
therapeutic target for sensory neuropathy in diabetic hearts 
[201, 202]. Taken together, these results suggest a novel role 
for NGF as a modulator of cardiac function and a potential 
link and biomarker for diabetic neuropathy and heart failure. 
ROLE OF NGF IN KIDNEY DEVELOPMENT AND 
DIABETIC NEPHROPATHY 
  In the development of the kidney, mesenchymal and 
epithelial interactions play a significant role. Interactions 
between the epithelial ureter bud and the mesenchyme 
initiate the development of the metanephric kidney. The 
mesenchyme stimulates the ureter to grow and branch, 
allowing differentiation into the collecting ducts. In turn, the 
ureter induces a part of the mesenchyme to convert into new 
epithelium. Recently, receptors for growth factors were 
expressed focally in the interacting epithelium and 
mesenchyme [203]. NGF is critically involved in kidney 
development. p75NTR persists at a lower level in adults in 
glomeruli and a subpopulation of renal interstitial cells. It is 
expressed during later stages of glomerulogenesis, where it 
is limited to the mesangium [204]. A recent report showed 
that NGF and p75NTR are over-expressed in the kidneys of 
patients affected by various renal disorders, and it was 
hypothesised that this growth factor may be involved in the 
pathophysiology of inflammatory kidney diseases including 
diabetic nephropathy [14, 205]. This hypothesis is also 
supported by the observation that NGF and its receptors are 
markedly expressed in renal disorders that are characterised 
by the enhanced presence of mast cells, macrophages and 
lymphocytes, cells that are known to produce and release 
NGF [17, 206].  
THE CONNECTION AMONG T2DM, CD, AD AND 
DEMENTIA 
  Risk factors such as hypertension, T2DM and 
hypercholesterolaemia increase the risk of both VD and AD 
[207, 208]. VD is caused by decreased or interrupted 
circulation of the blood flow to parts of the brain, and it is 
predominantly caused by cerebrovascular diseases (CVD), 
CD or stroke. Among the cardiovascular risk factors related 
to VD are hypertension, atherosclerosis, CAD, T2DM and 
smoking. Risk factors for stroke do not independently 
contribute to dementia, but commonly occur in clusters of 
risk factors [209]. 
  T2DM also contributes to microvascular changes in the 
brain, which in turn contribute to cognitive dysfunction and 
stroke [210-214]. Hyperglycaemia is generally accepted to 
be the major cause of diabetic microvascular complications 
and may play an important role in the development of 
macrovascular diseases. This condition allows cholesterol to 
build up in the walls of the blood vessels to form plaques 
that inhibit the heart-mediated oxygen and nutrition supply 
to various tissues and organs, including the brain [215]. The 
Framingham study also showed that the risk of developing 
congestive heart failure was increased in patients with 
T2DM and that the relative impact of diabetes on congestive 
heart failure was even greater than that for coronary heart 
disease [216].  
  Two major types of heart and blood vessel diseases 
common in people with diabetes are CAD and CVD. CAD is 
also called ischemic heart disease and is caused by the 
hardening or thickening of the blood vessel walls. The blood 
vessels are blocked by fatty deposits that reduce the blood 
supply to the heart, resulting in a heart attack. In contrast, 
CD affects blood flow to the brain, leading to the 
development of CVD and strokes. Brain cells are then 
deprived of oxygen and subsequently undergo apoptosis 
[217]. This decreased blood flow to the brain increases the 
risk of micro- and macrovascular diseases, which ultimately 
lead to dementia and stroke [218].  
  Hypertension is also associated with brain atrophy, large 
and small artery infarction and white matter lesion 
progression due to altered auto-regulation of blood flow to 
the brain. In ischaemic white matter lesions, long-term 
hypertension causes a narrowing of the lumen of the small 
arteries and arterioles that nourish the deep white matter. 
These vascular factors could directly affect the development 
of AD by causing neuronal death and the accumulation of 
plaques and tangles [219]. Small artery disease causes 
periventricular white matter ischaemia and lacunar strokes 
that manifest as VD [220].  
  Diabetes and ischaemic heart disease seem to enhance 
myocardial dysfunction, which leads to accelerated heart 
failure (diabetic cardiomyopathy). Thus, patients with 
diabetes are unusually prone to congestive heart failure. 
Several factors that probably underlie diabetic 
cardiomyopathy include severe coronary atherosclerosis, 
prolonged hypertension, chronic hyperglycaemia, 
microvascular disease, glycosylation of myocardial proteins 
and autonomic neuropathy [221]. Atherosclerosis is the 
major cause of dementia and increases the risk of AD. Thus, 
patients with diabetes often develop CD and CVD that in 
turn result in atherosclerosis which induces cerebral 
hypoperfusion, thus leading to cerebral hypoxia. These 
conditions destabilise synaptic connections and neuronal 
activity, gradually evolving into a neurodegenerative process 
characterised by the formation of SPs, NFTs and amyloid 
angiopathy as observed in VD or AD (Fig. 10) [222, 223].  44    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
FUTURE DIRECTIONS AND TREATMENTS OF AD 
Insulin-Degrading Enzyme (IDE) as a Therapeutic 
Target for the Treatment of AD 
  Insulin is catabolised by IDE, which also degrades other 
compounds such as IGFI, IGFII, amylin, intra- and 
extracellular A, glucagon, -endorphin and dynorphins as 
well as the AICD fragment produced by the -secretase 
cleavage of APP [224, 225]. IDE is abundant in the cytosol 
and in peroxisomes. In addition, IDE is found in the rough 
ER (RER), the plasma membrane, and the extracellular 
environment. Increased brain levels of insulin should 
effectively inhibit the degradation of A by IDE. This would 
consequently enhance A neurotoxicity and aid in AD 
progression [226]. IDE is part of the negative feedback loops 
that control insulin action. LRP and RAGE are involved in 
receptor-mediated flux of A across the BBB (Fig. 11). As 
mentioned earlier, LRP is a multifunctional signalling and 
scavenger receptor that consists of a heavy chain capable of 
binding a variety of ligands such as ApoE and 2-
macroglobulin (2M).  2M is a protein that is capable of 
binding A with high specificity and thus preventing its 
fibrillisation [227]. 2M is found in neuritic plaques in AD 
brains and plays a major role in A clearance via LRP [228]. 
A can be transported across the BBB and exported out of 
the brain into the bloodstream either by directly binding to 
LRP or by binding to the LRP ligands ApoE and 2M. 
While LRP appears to mediate the efflux of A from the 
brain to the periphery, RAGE has been strongly implicated 
in A influx into the CNS. Thus, soluble A can be removed 
from the brain via  two fundamental pathways: either by 
enzymatic degradation (for instance via IDE) or by receptor-
mediated clearance via  LRP [229]. Once A crosses the 
BBB and enters the bloodstream, it can re-enter the brain via 
the RAGE receptor or be delivered to peripheral sites for 
degradation in the liver or kidney. Consequently, clearance 
of A from the brain is a therapeutic approach and can be 
considered for the prevention of AD [230-232]. 
ACYL-COA: CHOLESTEROL ACYLTRANSFERASE 
(ACAT) AS A THERAPEUTIC APPROACH FOR AD 
  ACAT is a protein that converts cholesterol to highly 
insoluble CEs. ACAT is essential for the regulation of 
intracellular cholesterol homoeostasis and the distribution of 
cholesterol throughout the body. ACAT is the enzyme that 
removes excess cholesterol from membranes and converts 
FC to CEs for storage purposes. ACAT has two different 
isoforms: ACAT1 and ACAT2. In human tissues, ACAT1 is 
expressed ubiquitously, with prominent protein expression in 
Kupffer cells (located in the liver) and macrophages, as well 
as neurons [233]. Expression of ACAT2 appears to be 
restricted to the liver and intestine, where it is hypothesised 
to be a major player in the responsiveness to dietary 
cholesterol. Elevated FC results in the activation of ACAT 
and the production of CE. A close relationship exists among 
ACAT, intracellular cholesterol trafficking, and the sterol 
regulatory element binding protein (SREBP) pathway. 
SREBP consists of a complex group of membrane proteins 
that regulate cholesterol homeostasis. ACAT keeps the levels 
of FC in the membrane under strict control [234]. This pool 
of FC ultimately regulates the SREBP pathway. In the brain, 
cholesterol can be either stored within the cell as FC or 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (10). Connection of T2DM, CAD, AD and Dementia. Blockage of heart vessels leads to atherosclerosis and heart attack, whereas 
blockage of the brain arteries results in VD and stroke.  Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (11). IDE as a therapeutic approach for AD. A is degraded by ApoE, IDE and 2M. A binds to IDE, which allows its degradation 
inside the CNS. The remaining A binds ApoE and 2M that pass through the BBB via LRP. A portion of soluble A can also efflux from 
the LRP to re-enter the brain via RAGE. The peripheral ApoE-A and 2M-A complexes enter the liver and kidney, where they are 
degraded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (12). AD is classified into two types, FAD and SAD. FAD is based on mutations in specific genes such as PS1, PS2 and APP, whereas 
SAD is based on various factors including hypercholesterolaemia, hyperglycaemia, and insulin resistance. These SAD factors lead to the 
formation of T2DM, cardiovascular diseases, kidney diseases, and ultimately neurovascular dementia, such as AD. 
converted into CEs and stored in cytoplasmic droplets. An 
increase in the intracellular levels of CE leads to increased 
A production, whereas inhibition of ACAT leads to 
decreased levels of CEs and increased intracellular FC. The 46    The Open Biochemistry Journal, 2010, Volume 4  Kumari and Heese 
latter sequence eventually leads to decreased A production. 
Thus, ACAT is also particularly important in the process of 
AD development. Pharmacological inhibitors of ACAT are 
available, and these inhibitors could reduce A production to 
decrease amyloid plaque formation in AD [235, 236].  
STATIN AS A THERAPEUTIC APPROACH FOR AD 
  Cholesterol synthesis in neurons is regulated by HMG-
CoA reductase. HMG-CoA reductase inhibitors are 
commonly known as statins. Different types of available 
statins include lovastatin (Mevacer), pravastatin (Prasiocor), 
simvastatin (Zocor), rosuvastatin (Crestor) and atorvastatin 
(Lipitor) [237, 238]. These statins competitively inhibit 
HMG-CoA reductase, which is a rate-limiting enzyme that 
catalyses the conversion of HMG-CoA to L-mevalonate, and 
reduce the formation of L-mevalonate. The latter is a key 
intermediate in cholesterol synthesis and aids in decreasing 
LDL cholesterol and increasing HDL cholesterol levels [239, 
240]. Statins inhibit both cholesterol and isoprenoid 
synthesis; therefore, it is important to determine their 
individual effects on APP processing [155, 241, 242]. The 
variable side chain of a statin determines its solubility across 
the BBB. Atorvastatin, lovastatin and simvastatin are 
lipophilic and cross into the brain readily, whereas 
cerivastatin (Baycol, Lipobay (removed from market)), 
fluvastatin (Lescol, Canef, Vastin) and pravastatin are 
hydrophilic and do not cross. Statin inhibitors also inhibit 
isoprenylation, which results in a reduction of membrane raft 
clustering involved in APP processing and A degradation 
[243, 244]. 
CONCLUSION 
  The parallel development of T2DM and CD is a 
compound risk factor for both VD and AD [245]. There are 
strong additional interactions with other risk factors, such as 
hypertension, hyperglycaemia and hyperinsulinaemia, 
hypercholesterolaemia, hyperlipidaemia, endothelial 
dysfunction, AGE formation and the ApoE4 genotype. A 
specific role of NGF as potential link (biomarker?) of these 
diseases, however, remains elusive [15, 17, 246]. 
Disturbances in insulin signalling pathways may contribute 
to cognitive decline such as that seen with AD [247]. The 
link among insulin resistance, cholesterol metabolism, CD 
and VD has opened a new arena for research in the field of 
cognitive functions affected by aging and related 
neurodegenerative diseases.  
ABBREVIATIONS 
ABCA1  =  ATP-binding cassette transporter A1 
ACAT =  Acyl-CoA:  Cholesterol  acyltransferase 
ACE =  Acetylcholinesterase 
AD =  Alzheimer’s  disease 
AGE  =  Advance glycation end products 
ApoE =  Apolipoprotein  E 
APP  =  Amyloid precursor protein 
ATP =  Adenosine  triphosphate 
A  =  Amyloid beta peptide 
BACE =  -site APP cleaving enzyme 
BAD  =  Bcl-2 associated death protein 
BBB =  Blood-brain  barrier 
bFGF  =  Basic fibroblast growth factor 
CAD   =  Coronary artery disease 
CD =  Cardiovascular  disease 
CE =  Cholesterol  esters 
CNS =  Central  nervous  system 
CREB  =  cAMP responsive element-binding protein 
CSF =  Cerebrospinal  fluid 
CTGF  =  Ciliary transcription growth factor 
CVD =  Cerebrovascular  disease 
DAG   =  Diacylglycerol 
DMPP =  Dimethylallyl  pyrophosphate 
DN =  Diabetic  nephropathy 
DPN  =  Diabetic peripheral neuropathy 
ECM =  Extracellular  matrix   
EGF  =  Epidermal growth factor 
ER =  Endoplasmic  reticulum 
ERK  =  Extracellular signal regulated kinase 
FAD  =  Familial Alzheimer’s disease 
FC =  Free  cholesterol 
FPP =  Farnesyl  pyrophosphate 
GLUT =  Glucose  transporter 
GPP =  Geranyl  pyrophosphate 
Grb2  =  Growth factor receptor-binding protein 2 
GSK-3/ = Glycogen  synthase  kinase-3/ 
HDL   =  High density lipoprotein 
IDDM  =  Insulin dependent diabetes mellitus 
IDE =  Insulin  degrading  enzyme 
IGF  =  Insulin-like growth factor 
IL-1 =  Interleukin-1 
IPP =  Isopentenyl  pyrophosphate 
IR =  Insulin  resistance 
IRS  =  Insulin receptor substrate 
JNK =  Jun-N-terminal  kinase 
LDL  =  Low density lipoprotein 
LDLR  =  Low density lipoprotein receptor 
LOAD  =  Late onset of Alzheimer’s disease 
LRP  =  LDL receptor related protein 
MAP =  Microtubule  associated  protein 
MAPK   =  Mitogen activated protein kinase 
NF-B =  Nuclear  factor-B 
NFTs =  Neurofibrillary  tangles Cardiovascular Dementia  The Open Biochemistry Journal, 2010, Volume 4    47 
NGF  =  Nerve growth factor 
NIDDM  =  Non insulin dependent diabetes mellitus 
NIRKO  =  Neuronal insulin receptor knockout mice 
NP =  Neurofibrillary  plaques 
p75NTR  =  p75 neurotrophin receptor 
PAD  =  Peripheral arterial disease 
PDGF  =  Platelet-derived growth factor 
PI3K =  Phosphoinositide-3  kinase 
PKB  =  Protein kinase B/Akt 
PKC  =  Protein kinase C 
PLC =  Phospholipase  C 
PS1 =  Presenilin  1 
PS2 =  Presenilin  2 
RAGE  =  Receptor of advanced glycation end products 
ROS  =  Reactive oxygen species 
SAD  =  Sporadic Alzheimer’s disease 
SH2  =  Src homology 2 
SOS  =  Son of sevenless 
SP =  Senile  plaque 
SREBP  =  Sterol regulatory element binding protein 
T1DM  =  Type 1 diabetes mellitus 
T2DM  =  Type 2 diabetes mellitus 
TGF-/  =  Transcription growth factor-/ 
TIA   =  Transient ischaemic attacks 
TRK  =  Tyrosine receptor kinase 
VD =  Vascular  dementia 
VEGF  =  Vascular endothelial growth factor 
VLDL  =  Very low density lipoprotein 
2M =  2-Macroglobulin 
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